Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations

Prior treatment

• Prior liver or heart transplantation.
• Expected use of continuous intravenous inotropic therapy in the next 6 months.

Other illness

• Active malignancy or non-amyloid disease with expected survival of less than 1 year.
• Heart failure, in the opinion of the investigator, primarily caused by severe left-sided valve disease. Note: if valve was repaired, subject may be considered as no longer with severe valve disease.Heart failure, in the opinion of the investigator, primarily caused by either valve disease or ischemic heart disease.
• Heart failure, in the opinion of the investigator, primarily caused by ischemic heart disease.
• Impairment from stroke, injury or other medical disorder that precludes participation in the study.
• Disabling dementia or other mental or behavioral disease.

Lab values

• Chronic kidney disease with eGFR \<15 mL/min/1.73 m2 or ESRD.

Other

• Primary amyloidosis (AL) or secondary amyloidosis (AA).
• Ventricular assist device or anticipated within the next 6 months.
• Enrollment in a clinical trial not approved for co-enrollment.
• High risk for non-adherence as determined by screening evaluation.
• Inability or unwillingness to comply with the study requirements.
• Weight \>350 lb.
• Nursing home resident.
• Other reason that would make the subject inappropriate for entry into this study.

• Black or Hispanic of Caribbean origin.
• Age ≥ 60 years.
• Diagnosis of heart failure, confirmed by one of two methods:
  • Modified criteria utilized by Rich et al. which include a history of acute pulmonary edema or the occurrence of at least two of the following that improved with diuretic therapy without another identifiable cause: dyspnea on exertion, paroxysmal nocturnal dyspnea, orthopnea, bilateral lower extremity edema or exertional fatigue, and
  • National Health and Nutrition Examination Survey (NHANES) congestive heart failure (CHF) criteria with a score ≥3.
• Left ventricular septal OR inferolateral wall thickness ≥12 mm by echocardiography.
• Left ventricular Ejection fraction \>30% by echocardiography.
• Able to understand and sign the informed consent document after the nature of the study has been fully explained.